Steve Abrams

A commercial-stage pharmaceutical company in its US$46m follow-on offering led by Cowen and Cantor Fitzgerald.

A commercial-stage pharmaceutical company in its US$100m and US$50m follow-on offerings led by Jefferies, Cowen, and Piper Jaffray.

A commercial-stage pharmaceutical company in its US$70m follow-on offering and US$90m at-the-market offering.

A clinical-stage pharmaceutical company in its US$50m at-the-market offering.

An Australian-based clinical-stage pharmaceutical company in its US$40m private placement.

A clinical-stage biotechnology company in its US$40m and US$30m follow-on offerings and its US$35m at-the-market offering.

A publicly traded biotechnology company in its US$63m sale.

A publicly traded commercial-stage pharmaceutical company in an acquisition of a privately held specialty pharmaceutical company.

A pre-clinical-stage pharmaceutical company in its US$48m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.*

A clinical-stage pharmaceutical company in its US$80m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.*

A NASDAQ Global Market developer and supplier of injectable drug delivery systems in a US$45m underwritten offering of common stock.*

A clinical-stage biopharmaceutical company in its US$40m at-the-market equity program led by Cowen and Company.*

A publicly traded clinical-stage pharmaceutical company in a US$65.6m underwritten offering of common stock.*

A provider of integrated clinical documentation solutions for the U.S. health care system in a US$130m acquisition.*

A provider of integrated promotional outsource services to life sciences companies in its US$55m acquisition.*

A specialty pharmaceutical company in its US$138m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.

A specialty pharmaceutical company in its acquisition of a commercial-stage specialty pharmaceutical company and related equity and debt financing.

A clinical-stage oncology company in its reverse merger into a NASDAQ-listed public company.

A specialty pharmaceutical company in its co-promotional agreement with a major orthopaedic company.

A commercial-stage specialty pharmaceutical company in its US$120m follow-on public offering through a syndicate of underwriters led by Jefferies and Piper Jaffray.

Arbutus Biopharma Corp. on an at-the-market equity offering led by Jefferies.